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Abstract
Major depressive disorder (MDD) is a common but serious psychiatric disorder with significant levels of morbidity and
mortality. Recent genome-wide association studies (GWAS) on common variants increase our understanding of MDD;
however, the underlying genetic basis remains largely unknown. Many studies have been proposed to explore the
genetics of complex diseases from a viewpoint of the “missing heritability” by considering low-frequency and rare
variants, copy-number variations, and other types of genetic variants. Here we developed a novel computational and
statistical strategy to investigate the “missing heritability” of MDD. We applied Hamming distance on common, low-
frequency, and rare single-nucleotide polymorphism (SNP) sets to measure genetic distance between two individuals,
and then built the multi-dimensional scaling (MDS) pictures. Whole-exome genotyping data from a Los Angeles
Mexican-American cohort (203 MDD and 196 controls) and a European-ancestry cohort (473 MDD and 497 controls)
were examined using our proposed methodology. MDS plots showed very significant separations between MDD
cases and healthy controls for low-frequency SNP set (P value < 2.2e−16) and rare SNP set (P value= 7.681e−12). Our
results suggested that low-frequency and rare variants may play more significant roles in the genetics of MDD.
Introduction
Major depressive disorder (MDD) is a common mental
illness with tremendous medical, economic, and social
impact. MDD, as a principal contributor to disease load
worldwide, leads to high levels of morbidity and mortal-
ity1–5. One significant avenue for preventing and treating
depression lies in uncovering the genetics of this condi-
tion6,7. Despite rapid advances on genome-wide associa-
tion studies (GWAS)8–10, little is understood about its
fundamental biological basis and much further research
needs to be carried out to fully unravel the genetic ele-
ments that confer susceptibility to this disorder11,12.
Many studies have been proposed to explore the genetic
causes of complex diseases from a point view of the
“missing heritability”13–16. For example, some genetic
effects are not owing to the common single-nucleotide
polymorphisms (SNPs) examined in the candidate-gene
studies or GWAS, but due to low-frequency and rare
variants, copy-number variations, and other types of
genetic mutations17. Actually, GWAS focus on the iden-
tification of significant common (minor allele frequency
(MAF) ≥ 5%) variants, thus analyses of low-frequency
(0.5% ≤MAF < 5%) and rare (MAF < 0.5%) variants would
be promising to elucidate additional disease risk or trait
variability18. Furthermore, using next-generation
sequencing, family-based linkage analysis has also pro-
vided an important way to understand the role of rare
variants in disease etiology19,20. For example, some family-
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control studies applied Hamming distance to identify
disease genes based on sequencing data21,22. However,
high-priced sequencing expenses are currently a concern
that restricts acquiring large datasets.
Recently, we have applied GWAS and rare-variant
analysis to investigate the genetics of MDD based on a
whole-exome genotyping data from a Mexican-American
cohort in Los Angeles and a replication European-
ancestry cohort23. Our results suggested that the “miss-
ing heritability” in MDD may be partly explained by rare
variants, because most of the functional variations
detected in the cohorts were rare. In this study, we
designed a novel computational and statistical strategy to
further investigate this conclusion. In our methodology,
we used Hamming distance on common, low-frequency,
and rare SNP sets to measure the genetic distance
between two individuals. Then we built the multi-
dimensional scaling pictures, in which separation
between MDD cases and healthy controls revealed valu-
able information for hidden genetic factors of major
depression. The corresponding statistical results in the
pictures were reported.
Materials and methods
The two cohorts used in this study
In our previous work23, we have investigated a cohort of
MDD cases (n= 203) and controls (n= 196) of Los
Angeles Mexican-Americans. They were mostly recent
immigrants born in Mexico and experienced high levels of
hyperactivation of the hypothalamic-pituitary-adrenal axis
related to distress, challenges, and acculturation issues
caused by immigration. MDD were diagnosed using the
Structured Clinical Interview for DSM-IV (Diagnostic and
Statistical Manual IV edition) (SCID, for abbreviation).
Subjects met the diagnostic criteria for current, unipolar
major depressive episode, attended a pharmacogenetic
study on antidepressant treatment, and had an initial 21-
Item Hamilton Depression Rating Scale (HAM-D21 for
abbreviation) score of ≥18 with item number 1 (depressed
mood) rated ≥2. Controls responded that they were in
good health and replied questionnaires about accultura-
tion. But they were not screened for medical illnesses and
did not respond to structured psychiatric interviews. The
controls were also Mexican-American and recruited from
the same community in Los Angeles. The control group
have similar sex ratio and age distribution (mean and
standard error) to the MDD group (see Table S1). Parti-
cipants submitted written informed consent, and their
demographic, epidemiological, and clinical descriptions
were previously described in detail24–26. We have regis-
tered this study in ClinicalTrials.gov (NCT00265291). The
research was approved by the Institutional Review Boards
of the University of California Los Angeles and University
of Miami, USA, and by the Human Research Ethics
Committees of the Australian National University and
Bellbery Ltd, Australia.
We also included the European-ancestry cohort of
MDD cases (n= 473) and controls (n= 497), which was
used for replication in our previous study23. In this cohort,
the MDD group also have similar sex ratio and age dis-
tribution (mean and standard error) to the control group
(see Table S1). Those participants provided written
informed consent and were recruited under two proto-
cols: (1) Münster mood disorder studies (consisted of the
neuroimaging and the mood-in-flame studies), which
have been conducted by the Department of Psychiatry and
Psychotherapy, University of Münster, Münster, Ger-
many, and (2) the Characteristics of the Cognitive Func-
tion and Mood Study (CoFaM-Study) conducted by the
Discipline of Psychiatry, University of Adelaide, South
Australia, Australia27. The SCID/MINI (Mini Interna-
tional Neuropsychiatric Interview) was used to ascertain
that healthy controls were free from lifetime history of
psychiatric disorders; for this cohort, we also used DSM-
IV criteria and HAM-D21 for the main diagnostic of
MDD and mood assessment. The study on this cohort
was approved by Human Research Ethics Committee
protocols at the University of Münster, Germany, and
University of Adelaide and Flinders University, South
Australia, Australia.
Our previous power analysis on the same cohorts23
suggested that, when 100,000 variants are tested for
association studies, 200 cases and 200 controls are suffi-
cient to detect 80% true positives and a medium size of
effect defined by the Cohen’s h parameter. This value of
100,000 overcomes the numbers of SNPs in common,
low-frequency and rare-variant groups studied here.
Actually, based on the effect sizes for the 19 MDD GWAS
significant variants in the Mexican-American cohort23,
the post hoc statistical power ranges between >60% (SNP-
exm2249659, Cohen’s h= 0.335) and >99% (SNP-
exm1508600, Cohen’s h= 0.643). Cohen’s h suggests 0.2,
0.5, and 0.8 represent small, medium, and large effect
sizes, respectively; thus, it indicates that our study had
enough power to detect medium to large effect sizes for
current association tests.
Whole-exome SNP genotyping
The two cohorts were genotyped by the Australian
Genome Research Facility (North Melbourne, VIC, Aus-
tralia; www.agrf.org.au) using the Illumina HumanExome
BeadChip-12v1_A, in which exonic content consists of
>250,000 markers representing diverse populations and a
range of common conditions. All the human samples
passed the Illumina expected SNP calling rate (>99%).
Then we filtered the raw whole-exome SNPs by a pipeline
considering variant call rate, allele numbers, and
Hardy–Weinberg equilibrium deviations. For this follow-
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up study, we analyzed 83,898 SNPs for the Mexican-
American cohort and 121,174 SNPs for the European-
ancestry cohort, which remained after quality control
(QC) and filtering out criteria. Detailed QC and filtering
analyses have been well reported in our previous work23.
SNP classification and population stratification
Considering MAF, we divided the 83,898 SNPs in the
Mexican-American population into 27,575 common var-
iants, 17,838 low-frequency variants, and 38,485 rare
variants, and divided the 121,174 SNPs in the European-
ancestry population into 12,530 common variants, 12,902
low-frequency variants, and 95,742 rare variants. As
expected, we found that most SNPs are rare (MAF < 0.5%)
in the HumanExome BeadChip, because this chip has
been designed to concentrate on rare variants rather than
common ones28, which contrast to conventional genome-
wide genotyping arrays that do not tag low-frequency and
rare variants29.
We then used the four classes of SNPs (all, common,
low-frequency and rare) to check population stratifica-
tions of the two cohorts. PLINK software30, which pro-
vides a powerful tool for population stratification based
on pairwise identity-by-state (IBS) distance and multi-
dimensional scaling (MDS) plots, was used here.
Hamming distance between two individuals
In this study, we use Hamming distance31, a natural
distance without assuming any model mutation/sub-
stitution rate, to investigate the genetic distance between
two individuals based on a set of SNPs.
Table 1 Hamming distances of three subjects in an 8-SNP
set
Genotype SNP1 SNP2 SNP3 SNP4 SNP5 SNP6 SNP7 SNP8
(A/T) (G/T) (C/G) (C/T) (C/T) (A/G) (A/C) (C/T)
Subject X AT GG CG CC CC AG AC TT
Subject Y AA GG CC TT CT GG CC CT
Subject Z AA GG CC CC CT AA CC TT
SNP single-nucleotide polymorphism
Fig. 1 Population stratification based on IBS distance and MDS for Mexican-American cohort
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Let S be an SNP set which contains n SNPs. We
use SNPk to represent the SNP indexed k (k= 1, …, n).
Thus, S= {SNP1; SNP2; :::; SNPn}. Suppose that X
and Y are two individuals who have their own
genotypes on this SNP set S, namely and respectively,
SX and SY . Let SX be {SNPX1 ; SNP
X
2 ; :::; SNP
X
n } and SY be
{SNPY1 ; SNP
Y
2 ; :::; SNP
Y
n }. Then the Hamming distance




δðSNPXi ; SNPYi Þ; ð1Þ
where δða; bÞ ¼ 0 if a and b are the same
1 otherwise

, that is, the
number of positions at which the corresponding SNPs are
different on the SNP set S. Considering the size of the









Take Table 1 as a simple example, individuals X, Y, and
Z show their genotypes on an SNP set of eight SNPs. The
Hamming distance between X and Y is 7 (SNP1, SNP3,
SNP4, SNP5, SNP6, SNP7, and SNP8 are different).
Similarly, the Hamming distance between Y and Z is 3,
and the Hamming distance between X and Z is 5. Our
hypothesis was that if two individuals have closer Ham-
ming distance in this way, then those two individuals
would have closer genetic distance and more similar
phenotypes such as diseases or traits. We assume that Y
and Z have more similar phenotypes in the above
example.
Given a group of individuals, we can compute their
Hamming distance matrix based on a specific SNP set
such as common, low-frequency, or rare-variant set. After
obtaining the distance matrix between all pairs of indivi-
duals, MDS approach32 can be used to observe the dis-
tance relationships among those individuals in a two-
dimensional graph. The display of scatters representing
individuals which shows separating variability between
MDD cases and healthy controls can reveal interesting
genetic information hidden in the SNP sets. Then for
Fig. 2 Population stratification based on IBS distance and MDS for European-ancestry cohort
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statistical analysis, Hotelling’s T2 test for two independent
samples is used to examine whether the means of the two
groups (case and control) are equal.
Code availability
The codes (by R software; www.r-project.org) of data
analysis for this study can be accessed from the authors.
Results
Population stratification
In Figs. 1 and 2, we presented the population stratifi-
cation results based on all, common, low-frequency, and
rare SNP sets for the Mexican-American cohort and the
European-ancestry cohort. Although several far outliers
are found in Mexican-American cohort for low-frequency
and rare SNPs and in European-ancestry cohort for rare
SNPs, there is no significant separation between depres-
sed cases (blue points) and controls (red points) in the
IBS-MDS plots.
MDS on Hamming distance
In Fig. 3 we presented MDS results on Hamming dis-
tance for all, common, low-frequency, and rare SNP sets
of the Mexican-American cohort. For common SNPs,
there is no significant separation between MDD cases
(blue points) and controls (red points). However, for low-
frequency and rare SNPs, we found that all the healthy
controls were scattered in the lower half-plane, and all
points in the upper half-plane were blue points repre-
senting depressed cases. We use Hotelling’s T2 test to
statistically examine these visual separations between case
and control points in the MDS plane. For common var-
iants, the result is P value= 5.891e−05 and T2 statistic=
9.983. For low-frequency variants, the Hotelling’s T2 test
result is Pvalue <2.2e−16 and T2 statistic= 42.958. For
rare variants, the Hotelling’s T2 test result is Pvalue=
7.681e−12 and T2 statistic= 27.32. Therefore, the
separation of cases and controls shown in the MDS plane
is much more significant for low-frequency and rare SNPs
than for common SNPs.
In Fig. 4, we showed the results of MDS on Hamming
distance for all, common, low-frequency, and rare SNP
Fig. 3 MDS visualization based on Hamming distance for Mexican-American cohort
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sets of the European-ancestry cohort. For all the SNP sets,
we see that there is no significant visual separation
between MDD cases (blue points) and controls (red
points) in the MDS planes. The same results can also be
found in Figure S1 by excluding some far outliers.
Discussion
Genetic factors play important roles in the susceptibility
to major depression, as indicated by family, twin, and
adoption studies33. The heritability of MDD is estimated
to range between 40 and 70%34. In this article, we
designed a novel methodology to explore the “missing
heritability” of MDD. The significant separations between
cases and controls for low-frequency and rare variants in
the planes of MDS on Hamming distance supported our
previous conclusion23 that most of the functional variants
detected in the Mexican-American cohort were rare. The
corresponding statistical results also show that the
separation for low-frequency and rare SNPs is much more
significant than for common SNPs. Thus, our findings
further suggest that low-frequency and rare variants may
play more significant roles in the development of MDD.
Low-frequency and rare variants are currently not tagged
by conventional genome-wide genotyping arrays, thus
they may represent an important but understudied com-
ponent of MDD genetics29. There are many different
types of technical designs that identify low-frequency and
rare variants. In the current study, we applied whole-
exome-wide genotyping array data, which are relatively
cost-effective. With the rapid development of next-
generation sequencing technologies (whole-genome
sequencing, whole-exome sequencing, and targeted
sequencing of candidate genes), it is now possible to
collect most or even all low-frequency and rare genetic
variants in large samples and test their roles in human
disease risk35–37. Thus, future work would be needed to
further investigate our methodology on much larger SNP
sets.
The traditional genetic distance38 considers mutation
rates and is designed as a measure of genetic divergence
Fig. 4 MDS visualization based on Hamming distance for European-ancestry cohort
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between populations within a species. Therefore, it is not
appropriate to examine the genetic variation associated
with a complex disorder within a human population,
namely Mexican-American. In this work, Hamming dis-
tance was used to investigate the genetic distance between
two individuals based on their SNP sets. As sequencing
costs are currently dropping further, we may examine
single-nucleotide variants (SNVs) which involve much
more individual genetic information. For example, we
recently proposed a new concept of SNV proportion in
genes and employed it to develop a predictive approach
for major depression39. Using similar classification and
cluster analysis methods, a potential tool for MDD diag-
nosis could also be constructed based on Hamming dis-
tance and low-frequency/rare SNPs.
Using our methodology with a case–control study, we
could examine the effect of a group of variants within a
specific range of MAF. The design and methodology we
have developed can also be extended to other complex
disorders. Our approach based on exome genotyping
array or sequencing data may reveal the “missing herit-
ability” resulted from allele frequency for many complex
diseases.
Our European-ancestry cohort failed to show significant
separations of cases and controls in the MDS planes on
Hamming distance. The reasons could be as follows. First,
MDD is clearly a gene–environment interaction dis-
order34. Our Mexican-American cohort is comprised of
first-generation individuals (60%) who have experienced
significant levels of stress and hyperactivation of the
hypothalamic-pituitary-adrenal axis related to accultura-
tion issues40,41. In contrast to the European-ancestry
cohort, the significant stressful life events for Mexican-
Americans could cause much higher levels of depression.
Therefore, the depression effect differences between case
and control in two cohorts may be large. Further studies
using our methodology could be tested on a larger size of
European-ancestry sample. Second, the European-
ancestry cohort that we studied have much lower levels
of genetic variants. In our previous work23, whole-genome
sequencing analyses of a subset of the two cohorts
revealed that European-ancestry subjects have a sig-
nificantly reduced (around 50%) number of SNVs com-
pared with Mexican-American subjects. For this reason,
the roles of low-frequency and rare variants may vary
across populations.
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